This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haspolat, S. Articles by Yegin, O. Search for Related Content PubMed PubMed Citation Articles by Haspolat, S. Articles by Yegin, O. Social Bookmarking                   What's this?

Interleukin-1β, Interleukin-1 Receptor Antagonist Levels in Patients With Subacute Sclerosing Panencephalitis and the Effects of Different Treatment Protocols

Department of Pediatric Neurology, Akdeniz University Medical School, Antalya, Turkey, senay{at}med.akdeniz.edu.tr

Banu Anlar, MD

Department of Pediatric Neurology Hacettepe University Medical School

Gülsen Köse, MD

Department of Pediatrics Ankara Social Security Hospital, Ankara, Turkey

Mesut Coskun, MSc

Department of Pediatric Immunology Akdeniz University Medical School, Antalya, Turkey

Olcay Yegin, MD

Department of Pediatric Immunology Akdeniz University Medical School, Antalya, Turkey

Subacute sclerosing panencephalitis is a rare progressive inflammatory disease of the central nervous system caused by a persistent aberrant measles virus infection. Cytokines are polypeptides that regulate immune responses and inflammatory reactions. Interleuldn-1β has been implicated as a central mediator of tissue damage and destruction in a number of central nervous system diseases. Interleukin-1 receptor antagonist could function as an important anti-inflammatory cytokine. We studied interleukin-1β and interleukin-1 receptor antagonist levels in the cerebrospinal fluids of patients with subacute sclerosing panencephalitis and evaluated the effects of different treatment protocols on these cytokines. Interleukin-1β and interleukin-1 receptor antagonist levels were measured in 15 patients who had a recent diagnosis of subacute sclerosing panencephalitis (group 1), 6 patients who had been treated with isoprinosine (group 2), 5 patients with intraventricular interferon- (group 3), and 6 patients with interferon-β (group 4). The results were compared within the groups and also with the results of 10 patients with other neurologic disease (group 5).The interleukin-1β concentrations in cerebrospinal fluid and sera were all below the detection limits (3.9 pg/mL). Interleukin-1 receptor antagonist levels were not statistically different, except for the group treated with intraventricular interferon-. Interleukin-1 receptor antagonist levels were 170 ± 52, 175 ± 58, 1605 ± 518, 77.5 ± 24, and 108 ± 18 pg/mL in groups 1 to 5, respectively. Interleukin-1 receptor antagonist levels and cerebrospinal fluid serum ratios were significantly increased during interferon- treatment. In conclusion, interleukin-1 and interleukin-1 receptor antagonist levels were not elevated in the patients with subacute sclerosing panencephalitis. The only treatment protocol that affects interleukin-1 receptor antagonist levels in cerebrospinal fluid was intraventricular interferon-. Further studies on higher numbers of patients may better document the immunologic status of patients with subacute sclerosing panencephalitis and the effects of different treatment modes. (J Child Neurol 2001;16:417-420).

Journal of Child Neurology, Vol. 16, No. 6, 417-420 (2001)
DOI: 10.1177/088307380101600606


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?